Gastrointestinal AEs were the commonest AEs leading to treatment discontinuation from the neratinib arm of study 3004, particularly diarrhoea. Study 6201 included a similar population to study 3004, and employed loperamide prophylaxis. The rate of discontinuations due to diarrhoea is similar for both studies. The pattern was similar for dose reductions.